MEDPACE HOLDINGS INC

Medpace (MEDP) saw a modest Q3 2026 revenue rise and a $1 billion buy‑back boost, yet market confidence dips as earnings guidance stays vague and share price lags peers.

Medpace’s Q3 2026 earnings rise and new $1bn share‑repurchase plan signal strategic growth and flexible value‑creation for investors.

Medpace shares edge 0.19% higher at $630.39, briefly above its 200‑day SMA, amid mixed market sentiment and a 52‑week range of $373–$678. Click for a detailed snapshot.